Q4 2024 Earnings Call Transcript February 20, 2025 Repligen Corporation beats earnings expectations. Reported EPS is $0.44, ...

However, developing effective cyclic peptides presents numerous challenges, including poor pharmacokinetics, efficacy, and toxicity. Traditional methods like liquid chromatography tandem-mass ...

Repligen (NASDAQ:RGEN) Corporation reported its fourth-quarter 2024 earnings, surpassing analyst expectations with an earnings per share (EPS) of $0.44 against a forecast of $0.41. The company ...

Repligen (NASDAQ:RGEN) Corporation reported its fourth-quarter 2024 earnings, surpassing analyst expectations with an earnings per share (EPS) of $0.44 against a forecast of $0.41. The company also ...